Literature DB >> 6374868

Main causes of death in cirrhosis.

P Schlichting, E Christensen, L Fauerholdt, H Poulsen, E Juhl, N Tygstrup.   

Abstract

The main causes of 436 deaths among 532 patients with cirrhosis followed up for up to 16 years constituted liver failure (24%), liver failure with gastrointestinal bleeding (13%), gastrointestinal bleeding (14%), primary liver cell carcinoma (4%), other liver-related causes (2%), infections (7%), cardiovascular diseases (22%), extrahepatic malignancies (9%), and other non-liver-related causes (5%). Totally, 57% died of liver-related causes. A high frequency of liver-related death was found among patients with a short observation time, high biochemical activity, pronounced change in liver architecture, ascites, and other signs of a poor prognosis at the time of diagnosis. The findings favoured the hypothesis that cirrhosis of the liver is a disease with an initial active and a subsequent inactive phase. Half of the patients were treated with prednisone, but this had no detectable influence on the distribution of causes of or on the frequency of single causes of death as infections or gastrointestinal bleeding. The group of patients responding favourably to prednisone treatment with regard to survival (non-alcoholic women without ascites) showed causes of death not different from those of the total material.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6374868     DOI: 10.3109/00365528309182110

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  14 in total

Review 1.  Non-variceal gastrointestinal bleeding in patients with liver cirrhosis: a review.

Authors:  M Kalafateli; C K Triantos; V Nikolopoulou; A Burroughs
Journal:  Dig Dis Sci       Date:  2012-06-04       Impact factor: 3.199

2.  Distinctive aspects of peptic ulcer disease, Dieulafoy's lesion, and Mallory-Weiss syndrome in patients with advanced alcoholic liver disease or cirrhosis.

Authors:  Borko Nojkov; Mitchell S Cappell
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

3.  Trends in mortality after hospital admission for liver cirrhosis in an English population from 1968 to 1999.

Authors:  S E Roberts; M J Goldacre; D Yeates
Journal:  Gut       Date:  2005-06-24       Impact factor: 23.059

Review 4.  Extrahepatic Manifestations in Alcoholic Liver Disease.

Authors:  Preetam Nath; Anil C Anand
Journal:  J Clin Exp Hepatol       Date:  2022-02-25

5.  Outcome prediction for patients with cirrhosis of the liver in a medical ICU: a comparison of the APACHE scores and liver-specific scoringsystems.

Authors:  C A Zauner; R C Apsner; A Kranz; L Kramer; C Madl; B Schneider; B Schneeweiss; K Ratheiser; F Stockenhuber; K Lenz
Journal:  Intensive Care Med       Date:  1996-06       Impact factor: 17.440

6.  Does intubation really equal death in cirrhotic patients? Factors influencing outcome in patients with liver cirrhosis requiring mechanical ventilation.

Authors:  Christian Rabe; Volker Schmitz; Michael Paashaus; Annemarie Musch; Helga Zickermann; Franz-Ludwig Dumoulin; Tilman Sauerbruch; Wolfgang H Caselmann
Journal:  Intensive Care Med       Date:  2004-06-26       Impact factor: 17.440

7.  Propranolol in the primary prevention of upper gastrointestinal tract haemorrhage in patients with cirrhosis of the liver and oesophageal varices.

Authors:  J P Pascal; P Calès
Journal:  Drugs       Date:  1989       Impact factor: 9.546

Review 8.  Management of Acute Coronary Syndrome in Patients with Liver Cirrhosis.

Authors:  Taha Ahmed; Alla Y Grigorian; Adrian W Messerli
Journal:  Am J Cardiovasc Drugs       Date:  2021-05-29       Impact factor: 3.571

Review 9.  Hepatic hydrothorax: clinical features, management, and outcomes in 77 patients and review of the literature.

Authors:  Ricardo Badillo; Don C Rockey
Journal:  Medicine (Baltimore)       Date:  2014-05       Impact factor: 1.889

Review 10.  Capsule Endoscopy for Portal Hypertensive Enteropathy.

Authors:  Seong Ran Jeon; Jin-Oh Kim
Journal:  Gastroenterol Res Pract       Date:  2015-12-27       Impact factor: 2.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.